Cravath, Swaine & Moore LLP Logo
  • Practices
  • People
  • Careers
  • News & Insights
  • Practices
  • People
  • Careers
  • News & Insights
  • Our Story
  • The Cravath System
  • Diversity & Inclusion
  • Pro Bono
  • Alumni Journal
  • 200.Cravath

Cravath Publishes Summer 2026 Issue of Alumni Journal

Read More

People

Andrew M.
Wark

Partner, Corporate

awark@cravath.com
  • New York+1-212-474-1592
    • E-mail
    • Twitter
    • Facebook
    • LinkedIn
  • PDF
  • Vcard
  • Overview
  • Credentials
  • Featured Work
  • News & Insights

Andrew M. Wark focuses his practice on public and private mergers and acquisitions, shareholder activism defense and general corporate matters. Mr. Wark’s clients have included AngloGold Ashanti, AXA, Barrick Gold, Benchmark Electronics, CardWorks, Convey Health Solutions, Corteva, Cox Enterprises, Crown Castle, Eurazeo, Evolent Health, Fortress Transportation & Infrastructure Investors, Future Standard, GuideWell, Hapag‑Lloyd, IBM, Just Eat Takeaway.com, Olin, Peabody Energy, RELX Group, Sensata Technologies, TMX Group, Viatris and ViewRay.

Mr. Wark’s notable M&A transactions include representing:

  • TMX Group in its strategic investment in the pending $2.3 billion combination of MEMX and BOX;
  • Talkspace in its pending $835 million acquisition by Universal Health Services;
  • A consortium led by Robert A. Ortenzio, Martin F. Jackson and WCAS in the $3.9 billion acquisition of Select Medical;
  • Hapag-Lloyd in its over $4 billion pending acquisition of ZIM;
  • AngloGold Ashanti in its C$197 million acquisition of Augusta Gold;
  • Paragon 28 in its $1.2 billion acquisition by Zimmer Biomet;
  • CardWorks in its acquisition of Ally’s credit card business;
  • Just Eat Takeaway.com in the sale of Grubhub to Wonder;
  • Atalaya Capital Management in its $800 million sale to Blue Owl Capital;
  • Viatris in its divestitures totaling $3.6 billion in value, including the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses;

  • Viatris in its $750 million acquisitions of Oyster Point and Famy Life Sciences;

  • Newcrest in its A$28.8 billion acquisition by Newmont;
  • FS Investments (now Future Standard) in its combination with Portfolio Advisors, creating a $75 billion alternative investment firm;
  • Cowen in its $1.9 billion acquisition by TD;
  • Convey Health Solutions in its $1.1 billion take‑private acquisition by TPG Capital;
  • GuideWell in its $900 million combination with Triple-S Management;
  • The special committee of the board of Eidos Therapeutics in the $2.83 billion merger with BridgeBio Pharma;
  • Just Eat Takeaway.com in its $7.3 billion acquisition of Grubhub;
  • Barrick Gold in its proposed $42 billion merger and subsequent joint venture with Newmont Mining and its $18.3 billion merger with Randgold Resources;
  • RELX Group in its acquisition of Emailage;
  • Peabody Energy in its proposed joint venture with Arch Resources;
  • AXA in its $15.3 billion acquisition of XL;
  • Cincinnati Bell in its $650 million combination with Hawaiian Telcom and its $201 million acquisition of OnX Enterprise Solutions;
  • Eurazeo in its majority investment in WorldStrides;
  • Crown Castle in its $7.1 billion acquisition of Lightower and its $1.5 billion acquisition of FiberNet;
  • Alere in its $8 billion sale to Abbott Laboratories;
  • MarkWest Energy Partners in its $21 billion merger with MPLX;
  • IBM in its acquisition of Clearleap; and
  • Olin in its $5 billion Reverse Morris Trust acquisition of the chlorine value chain business of Dow Chemical.

Mr. Wark has also represented numerous companies and boards of directors regarding shareholder activism, including representing Benchmark Electronics in its cooperation agreement with Engaged Capital, Corteva in its agreement with Starboard, Evolent Health in its cooperation agreement with Engaged Capital, Sensata Technologies in its cooperation agreement with Elliott Management and ViewRay in its cooperation agreement with Hudson Executive Capital.

Mr. Wark has been recognized for his activism defense work by The Legal 500 US and for his work in mergers and acquisitions by IFLR1000. He was named an M&A “Rising Star” by The Deal in 2021 and has been recognized by Lawdragon as among the “500 Leading Dealmakers in America,” “500 Global Leaders in Crisis Management” and the “500 X – The Next Generation.” He also co‑authored the United States chapter of “Getting the Deal Through: Distressed M&A.”

Mr. Wark was born in Portland, Oregon. He received a B.S. from Duke University in 2010 and a J.D. from Columbia Law School in 2013, where he was a Harlan Fiske Stone Scholar and a Staff Editor of the Law Review.

Mr. Wark joined Cravath in 2013 and was elected a partner in 2020.

Mr. Wark’s notable M&A transactions include representing:

  • TMX Group in its strategic investment in the pending $2.3 billion combination of MEMX and BOX;
  • Talkspace in its pending $835 million acquisition by Universal Health Services;
  • A consortium led by Robert A. Ortenzio, Martin F. Jackson and WCAS in the $3.9 billion acquisition of Select Medical;
  • Hapag-Lloyd in its over $4 billion pending acquisition of ZIM;
  • AngloGold Ashanti in its C$197 million acquisition of Augusta Gold;
  • Paragon 28 in its $1.2 billion acquisition by Zimmer Biomet;
  • CardWorks in its acquisition of Ally’s credit card business;
  • Just Eat Takeaway.com in the sale of Grubhub to Wonder;
  • Atalaya Capital Management in its $800 million sale to Blue Owl Capital;
  • Viatris in its divestitures totaling $3.6 billion in value, including the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses;

  • Viatris in its $750 million acquisitions of Oyster Point and Famy Life Sciences;

  • Newcrest in its A$28.8 billion acquisition by Newmont;
  • FS Investments (now Future Standard) in its combination with Portfolio Advisors, creating a $75 billion alternative investment firm;
  • Cowen in its $1.9 billion acquisition by TD;
  • Convey Health Solutions in its $1.1 billion take‑private acquisition by TPG Capital;
  • GuideWell in its $900 million combination with Triple-S Management;
  • The special committee of the board of Eidos Therapeutics in the $2.83 billion merger with BridgeBio Pharma;
  • Just Eat Takeaway.com in its $7.3 billion acquisition of Grubhub;
  • Barrick Gold in its proposed $42 billion merger and subsequent joint venture with Newmont Mining and its $18.3 billion merger with Randgold Resources;
  • RELX Group in its acquisition of Emailage;
  • Peabody Energy in its proposed joint venture with Arch Resources;
  • AXA in its $15.3 billion acquisition of XL;
  • Cincinnati Bell in its $650 million combination with Hawaiian Telcom and its $201 million acquisition of OnX Enterprise Solutions;
  • Eurazeo in its majority investment in WorldStrides;
  • Crown Castle in its $7.1 billion acquisition of Lightower and its $1.5 billion acquisition of FiberNet;
  • Alere in its $8 billion sale to Abbott Laboratories;
  • MarkWest Energy Partners in its $21 billion merger with MPLX;
  • IBM in its acquisition of Clearleap; and
  • Olin in its $5 billion Reverse Morris Trust acquisition of the chlorine value chain business of Dow Chemical.

Mr. Wark has also represented numerous companies and boards of directors regarding shareholder activism, including representing Benchmark Electronics in its cooperation agreement with Engaged Capital, Corteva in its agreement with Starboard, Evolent Health in its cooperation agreement with Engaged Capital, Sensata Technologies in its cooperation agreement with Elliott Management and ViewRay in its cooperation agreement with Hudson Executive Capital.

Mr. Wark has been recognized for his activism defense work by The Legal 500 US and for his work in mergers and acquisitions by IFLR1000. He was named an M&A “Rising Star” by The Deal in 2021 and has been recognized by Lawdragon as among the “500 Leading Dealmakers in America,” “500 Global Leaders in Crisis Management” and the “500 X – The Next Generation.” He also co‑authored the United States chapter of “Getting the Deal Through: Distressed M&A.”

Mr. Wark was born in Portland, Oregon. He received a B.S. from Duke University in 2010 and a J.D. from Columbia Law School in 2013, where he was a Harlan Fiske Stone Scholar and a Staff Editor of the Law Review.

Mr. Wark joined Cravath in 2013 and was elected a partner in 2020.

Education

  • J.D., 2013, Columbia Law School
    Harlan Fiske Stone Scholar
  • B.S., 2010, Duke University

Admitted In

  • New York

Rankings

The Dealmaker Quarterly

  • Rising Star (2021)

IFLR1000

  • Mergers and Acquisitions - US (2025)

Lawdragon

  • 500 Leading Dealmakers in America (2025, 2024, 2023)
  • 500 Global Leaders in Crisis Management (2026, 2025)
  • 500 X – The Next Generation (2026-2023)

The Legal 500 US

  • Shareholder Activism: Advice to Boards (2026, 2025)

Deals & Cases

July 31, 2026

TMX Group’s Strategic Investment in the $2.3 Billion Combination of MEMX and BOX

On July 30, 2026, TMX Group, a global provider of data, listing services, trading markets, clearing facilities and other services to the global financial community, announced a definitive agreement to make a strategic investment in MEMX, an exchange operator and market technology provider. Concurrent with that transaction, BOX, a U.S. equity options market with both electronic and floor-based trading, will be combined with MEMX, and TMX Group will have an approximately 59% ownership interest in the combined business. Under the terms of the agreement, this transaction will create a consolidated U.S. exchange group with an enterprise value of approximately $2.3 billion. The new entity will be funded by an equity investment from TMX Group of approximately $800 million, a rollover of TMX’s existing equity interest in BOX, committed rollovers from a group of MEMX and BOX investors, comprised of key market participants, and an investment from a new financial partner. Cravath is representing TMX Group in connection with the transaction.

Deals & Cases

March 09, 2026

Talkspace’s Acquisition by UHS

On March 9, 2026, Universal Health Services, Inc. (“UHS”) announced that it has entered into a definitive agreement to acquire Talkspace, Inc. (“Talkspace”) for $5.25 per share. The enterprise value for the transaction is approximately $835 million. Cravath is representing Talkspace in connection with the transaction.

Deals & Cases

March 02, 2026

Select Medical’s $3.9 Billion Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson and WCAS

On March 2, 2026, Select Medical Holdings Corporation (“Select Medical”) announced that it has entered into a definitive agreement pursuant to which an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (“WCAS” and, together with Mr. Ortenzio and Mr. Jackson, the “Consortium”) will acquire all of the outstanding shares of common stock of Select Medical not already owned by the Consortium for a price per share of $16.50 in cash, representing an enterprise value of $3.9 billion, on the terms and subject to the conditions set forth in the merger agreement. Cravath is representing the buyer consortium in connection with the transaction.

Deals & Cases

February 16, 2026

Hapag-Lloyd’s Over $4 Billion Acquisition of ZIM

On February 16, 2026, Hapag‑Lloyd signed an agreement with ZIM Integrated Shipping Services Ltd. (“ZIM”), the world’s 10th largest container shipping line, under which Hapag‑Lloyd will acquire 100% of ZIM’s shares for a consideration of $35 per share in cash. The total transaction value amounts to over $4 billion. As part of the transaction, FIMI Opportunity Funds will take ownership of a carved‑out Israeli container liner business. Cravath is representing Hapag‑Lloyd in connection with the transaction.

Deals & Cases

July 17, 2025

AngloGold Ashanti’s Acquisition of Augusta Gold

On July 16, 2025, AngloGold Ashanti plc (“AngloGold Ashanti”), an independent, global gold mining company, announced that certain of its subsidiaries have entered into a definitive agreement with Augusta Gold Corp. (“Augusta Gold”) to acquire all issued and outstanding shares of common stock of Augusta Gold at a price of C$1.70 per share of common stock in cash. The price implies an enterprise value for Augusta Gold of approximately C$197 million (approximately $143 million). Cravath is representing AngloGold Ashanti as U.S. counsel in connection with the transaction.

Publications

March 11, 2026

HLS Forum on Corporate Governance Publishes Cravath’s Q4 2025 Newsletter on M&A, Activism and Corporate Governance

On March 10, 2026, the Harvard Law School Forum on Corporate Governance published Cravath’s latest quarterly newsletter on M&A, activism and corporate governance. The newsletter provides insight into practical points, key takeaways and relevant developments across the M&A, activism, tax, regulatory and corporate governance landscape during the fourth quarter of 2025. Contributors to this edition include partners G.J. Ligelis Jr., Evan A. Hill, Andrew M. Wark, Bethany A. Pfalzgraf and Edward O. Minturn.

Publications

January 16, 2026

HLS Forum on Corporate Governance Publishes Cravath’s Q3 2025 Newsletter on M&A, Activism and Corporate Governance

On January 15, 2026, the Harvard Law School Forum on Corporate Governance published Cravath’s latest quarterly newsletter on M&A, activism and corporate governance. The newsletter provides insight into practical points, key takeaways and relevant developments across the M&A, activism, restructuring, regulatory and corporate governance landscape during the third quarter of 2025. Contributors to this edition include partners G.J. Ligelis Jr., Evan A. Hill, Michael L. Arnold, Andrew M. Wark, Bethany A. Pfalzgraf and Edward O. Minturn.

Publications

October 24, 2023

SEC Adopts Rule Amendments To Modernize Beneficial Ownership Reporting

On October 20, 2023, Cravath prepared a memo for its clients entitled “SEC Adopts Rule Amendments To Modernize Beneficial Ownership Reporting.” The memo examines the U.S. Securities and Exchange Commission’s recently adopted final rule amendments to modernize beneficial ownership reporting under Sections 13(d) and 13(g) of the Securities Exchange Act of 1934. The memo outlines the final rule amendments’ changes and guidance related to deadlines and cut‑off times for Schedule 13D and Schedule 13G filings, structured data language, the application of Regulation 13D-G to certain derivative securities and the definition of “group” in existing statutory language.

Publications

March 17, 2023

Andrew Wark and Maggie Segall Author Chapter on U.S. Antitrust Enforcement Trends in Deal‑Making for the International Comparative Legal Guide’s “Mergers & Acquisitions 2023”

Cravath partners Andrew M. Wark and Margaret T. Segall authored a chapter for the International Comparative Legal Guide’s “Mergers & Acquisitions 2023,” which provides cross border insights into mergers and acquisitions and was published by Global Legal Group on March 16, 2023. The chapter, entitled “Key Drivers and Trends: Deal‑Making in an Era of Heightened Antitrust Enforcement,” examines how companies considering M&A transactions in the United States have faced an evolving antitrust landscape, including changed enforcement practices and merger review procedures.

Publications

December 01, 2022

Jed Zobitz, Paul Zumbro and Andrew Wark Co‑Author U.S. Chapter of Lexology Getting The Deal Through’s “Distressed M&A 2023”

Cravath partners George E. Zobitz, Paul H. Zumbro and Andrew M. Wark co‑authored the United States chapter of Lexology Getting The Deal Through’s “Distressed M&A 2023,” which was published in November 2022. The chapter surveys the current market climate and legal framework for distressed M&A and provides a comprehensive overview of these transactions. The authors address relevant considerations involving transaction structures and sale process, due diligence, valuation and financing, documentation, regulatory and judicial approvals, and dispute resolution.

Andrew M. Wark focuses his practice on public and private mergers and acquisitions, shareholder activism defense and general corporate matters. Mr. Wark’s clients have included AngloGold Ashanti, AXA, Barrick Gold, Benchmark Electronics, CardWorks, Convey Health Solutions, Corteva, Cox Enterprises, Crown Castle, Eurazeo, Evolent Health, Fortress Transportation & Infrastructure Investors, Future Standard, GuideWell, Hapag‑Lloyd, IBM, Just Eat Takeaway.com, Olin, Peabody Energy, RELX Group, Sensata Technologies, TMX Group, Viatris and ViewRay.

Mr. Wark’s notable M&A transactions include representing:

  • TMX Group in its strategic investment in the pending $2.3 billion combination of MEMX and BOX;
  • Talkspace in its pending $835 million acquisition by Universal Health Services;
  • A consortium led by Robert A. Ortenzio, Martin F. Jackson and WCAS in the $3.9 billion acquisition of Select Medical;
  • Hapag-Lloyd in its over $4 billion pending acquisition of ZIM;
  • AngloGold Ashanti in its C$197 million acquisition of Augusta Gold;
  • Paragon 28 in its $1.2 billion acquisition by Zimmer Biomet;
  • CardWorks in its acquisition of Ally’s credit card business;
  • Just Eat Takeaway.com in the sale of Grubhub to Wonder;
  • Atalaya Capital Management in its $800 million sale to Blue Owl Capital;
  • Viatris in its divestitures totaling $3.6 billion in value, including the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses;

  • Viatris in its $750 million acquisitions of Oyster Point and Famy Life Sciences;

  • Newcrest in its A$28.8 billion acquisition by Newmont;
  • FS Investments (now Future Standard) in its combination with Portfolio Advisors, creating a $75 billion alternative investment firm;
  • Cowen in its $1.9 billion acquisition by TD;
  • Convey Health Solutions in its $1.1 billion take‑private acquisition by TPG Capital;
  • GuideWell in its $900 million combination with Triple-S Management;
  • The special committee of the board of Eidos Therapeutics in the $2.83 billion merger with BridgeBio Pharma;
  • Just Eat Takeaway.com in its $7.3 billion acquisition of Grubhub;
  • Barrick Gold in its proposed $42 billion merger and subsequent joint venture with Newmont Mining and its $18.3 billion merger with Randgold Resources;
  • RELX Group in its acquisition of Emailage;
  • Peabody Energy in its proposed joint venture with Arch Resources;
  • AXA in its $15.3 billion acquisition of XL;
  • Cincinnati Bell in its $650 million combination with Hawaiian Telcom and its $201 million acquisition of OnX Enterprise Solutions;
  • Eurazeo in its majority investment in WorldStrides;
  • Crown Castle in its $7.1 billion acquisition of Lightower and its $1.5 billion acquisition of FiberNet;
  • Alere in its $8 billion sale to Abbott Laboratories;
  • MarkWest Energy Partners in its $21 billion merger with MPLX;
  • IBM in its acquisition of Clearleap; and
  • Olin in its $5 billion Reverse Morris Trust acquisition of the chlorine value chain business of Dow Chemical.

Mr. Wark has also represented numerous companies and boards of directors regarding shareholder activism, including representing Benchmark Electronics in its cooperation agreement with Engaged Capital, Corteva in its agreement with Starboard, Evolent Health in its cooperation agreement with Engaged Capital, Sensata Technologies in its cooperation agreement with Elliott Management and ViewRay in its cooperation agreement with Hudson Executive Capital.

Mr. Wark has been recognized for his activism defense work by The Legal 500 US and for his work in mergers and acquisitions by IFLR1000. He was named an M&A “Rising Star” by The Deal in 2021 and has been recognized by Lawdragon as among the “500 Leading Dealmakers in America,” “500 Global Leaders in Crisis Management” and the “500 X – The Next Generation.” He also co‑authored the United States chapter of “Getting the Deal Through: Distressed M&A.”

Mr. Wark was born in Portland, Oregon. He received a B.S. from Duke University in 2010 and a J.D. from Columbia Law School in 2013, where he was a Harlan Fiske Stone Scholar and a Staff Editor of the Law Review.

Mr. Wark joined Cravath in 2013 and was elected a partner in 2020.

Mr. Wark’s notable M&A transactions include representing:

  • TMX Group in its strategic investment in the pending $2.3 billion combination of MEMX and BOX;
  • Talkspace in its pending $835 million acquisition by Universal Health Services;
  • A consortium led by Robert A. Ortenzio, Martin F. Jackson and WCAS in the $3.9 billion acquisition of Select Medical;
  • Hapag-Lloyd in its over $4 billion pending acquisition of ZIM;
  • AngloGold Ashanti in its C$197 million acquisition of Augusta Gold;
  • Paragon 28 in its $1.2 billion acquisition by Zimmer Biomet;
  • CardWorks in its acquisition of Ally’s credit card business;
  • Just Eat Takeaway.com in the sale of Grubhub to Wonder;
  • Atalaya Capital Management in its $800 million sale to Blue Owl Capital;
  • Viatris in its divestitures totaling $3.6 billion in value, including the divestitures of its Over‑the‑Counter, Women’s Healthcare and Active Pharmaceutical Ingredients businesses;

  • Viatris in its $750 million acquisitions of Oyster Point and Famy Life Sciences;

  • Newcrest in its A$28.8 billion acquisition by Newmont;
  • FS Investments (now Future Standard) in its combination with Portfolio Advisors, creating a $75 billion alternative investment firm;
  • Cowen in its $1.9 billion acquisition by TD;
  • Convey Health Solutions in its $1.1 billion take‑private acquisition by TPG Capital;
  • GuideWell in its $900 million combination with Triple-S Management;
  • The special committee of the board of Eidos Therapeutics in the $2.83 billion merger with BridgeBio Pharma;
  • Just Eat Takeaway.com in its $7.3 billion acquisition of Grubhub;
  • Barrick Gold in its proposed $42 billion merger and subsequent joint venture with Newmont Mining and its $18.3 billion merger with Randgold Resources;
  • RELX Group in its acquisition of Emailage;
  • Peabody Energy in its proposed joint venture with Arch Resources;
  • AXA in its $15.3 billion acquisition of XL;
  • Cincinnati Bell in its $650 million combination with Hawaiian Telcom and its $201 million acquisition of OnX Enterprise Solutions;
  • Eurazeo in its majority investment in WorldStrides;
  • Crown Castle in its $7.1 billion acquisition of Lightower and its $1.5 billion acquisition of FiberNet;
  • Alere in its $8 billion sale to Abbott Laboratories;
  • MarkWest Energy Partners in its $21 billion merger with MPLX;
  • IBM in its acquisition of Clearleap; and
  • Olin in its $5 billion Reverse Morris Trust acquisition of the chlorine value chain business of Dow Chemical.

Mr. Wark has also represented numerous companies and boards of directors regarding shareholder activism, including representing Benchmark Electronics in its cooperation agreement with Engaged Capital, Corteva in its agreement with Starboard, Evolent Health in its cooperation agreement with Engaged Capital, Sensata Technologies in its cooperation agreement with Elliott Management and ViewRay in its cooperation agreement with Hudson Executive Capital.

Mr. Wark has been recognized for his activism defense work by The Legal 500 US and for his work in mergers and acquisitions by IFLR1000. He was named an M&A “Rising Star” by The Deal in 2021 and has been recognized by Lawdragon as among the “500 Leading Dealmakers in America,” “500 Global Leaders in Crisis Management” and the “500 X – The Next Generation.” He also co‑authored the United States chapter of “Getting the Deal Through: Distressed M&A.”

Mr. Wark was born in Portland, Oregon. He received a B.S. from Duke University in 2010 and a J.D. from Columbia Law School in 2013, where he was a Harlan Fiske Stone Scholar and a Staff Editor of the Law Review.

Mr. Wark joined Cravath in 2013 and was elected a partner in 2020.

Education

  • J.D., 2013, Columbia Law School
    Harlan Fiske Stone Scholar
  • B.S., 2010, Duke University

Admitted In

  • New York

Rankings

The Dealmaker Quarterly

  • Rising Star (2021)

IFLR1000

  • Mergers and Acquisitions - US (2025)

Lawdragon

  • 500 Leading Dealmakers in America (2025, 2024, 2023)
  • 500 Global Leaders in Crisis Management (2026, 2025)
  • 500 X – The Next Generation (2026-2023)

The Legal 500 US

  • Shareholder Activism: Advice to Boards (2026, 2025)

Deals & Cases

July 31, 2026

TMX Group’s Strategic Investment in the $2.3 Billion Combination of MEMX and BOX

On July 30, 2026, TMX Group, a global provider of data, listing services, trading markets, clearing facilities and other services to the global financial community, announced a definitive agreement to make a strategic investment in MEMX, an exchange operator and market technology provider. Concurrent with that transaction, BOX, a U.S. equity options market with both electronic and floor-based trading, will be combined with MEMX, and TMX Group will have an approximately 59% ownership interest in the combined business. Under the terms of the agreement, this transaction will create a consolidated U.S. exchange group with an enterprise value of approximately $2.3 billion. The new entity will be funded by an equity investment from TMX Group of approximately $800 million, a rollover of TMX’s existing equity interest in BOX, committed rollovers from a group of MEMX and BOX investors, comprised of key market participants, and an investment from a new financial partner. Cravath is representing TMX Group in connection with the transaction.

Deals & Cases

March 09, 2026

Talkspace’s Acquisition by UHS

On March 9, 2026, Universal Health Services, Inc. (“UHS”) announced that it has entered into a definitive agreement to acquire Talkspace, Inc. (“Talkspace”) for $5.25 per share. The enterprise value for the transaction is approximately $835 million. Cravath is representing Talkspace in connection with the transaction.

Deals & Cases

March 02, 2026

Select Medical’s $3.9 Billion Acquisition by Consortium Led by Robert A. Ortenzio, Martin F. Jackson and WCAS

On March 2, 2026, Select Medical Holdings Corporation (“Select Medical”) announced that it has entered into a definitive agreement pursuant to which an entity affiliated with a consortium led by Robert A. Ortenzio, Executive Chairman, Co-Founder and Director of Select Medical, Martin F. Jackson, Senior Executive Vice President of Strategic Finance and Operations of Select Medical, and Welsh, Carson, Anderson & Stowe (“WCAS” and, together with Mr. Ortenzio and Mr. Jackson, the “Consortium”) will acquire all of the outstanding shares of common stock of Select Medical not already owned by the Consortium for a price per share of $16.50 in cash, representing an enterprise value of $3.9 billion, on the terms and subject to the conditions set forth in the merger agreement. Cravath is representing the buyer consortium in connection with the transaction.

Deals & Cases

February 16, 2026

Hapag-Lloyd’s Over $4 Billion Acquisition of ZIM

On February 16, 2026, Hapag‑Lloyd signed an agreement with ZIM Integrated Shipping Services Ltd. (“ZIM”), the world’s 10th largest container shipping line, under which Hapag‑Lloyd will acquire 100% of ZIM’s shares for a consideration of $35 per share in cash. The total transaction value amounts to over $4 billion. As part of the transaction, FIMI Opportunity Funds will take ownership of a carved‑out Israeli container liner business. Cravath is representing Hapag‑Lloyd in connection with the transaction.

Deals & Cases

July 17, 2025

AngloGold Ashanti’s Acquisition of Augusta Gold

On July 16, 2025, AngloGold Ashanti plc (“AngloGold Ashanti”), an independent, global gold mining company, announced that certain of its subsidiaries have entered into a definitive agreement with Augusta Gold Corp. (“Augusta Gold”) to acquire all issued and outstanding shares of common stock of Augusta Gold at a price of C$1.70 per share of common stock in cash. The price implies an enterprise value for Augusta Gold of approximately C$197 million (approximately $143 million). Cravath is representing AngloGold Ashanti as U.S. counsel in connection with the transaction.

Publications

March 11, 2026

HLS Forum on Corporate Governance Publishes Cravath’s Q4 2025 Newsletter on M&A, Activism and Corporate Governance

On March 10, 2026, the Harvard Law School Forum on Corporate Governance published Cravath’s latest quarterly newsletter on M&A, activism and corporate governance. The newsletter provides insight into practical points, key takeaways and relevant developments across the M&A, activism, tax, regulatory and corporate governance landscape during the fourth quarter of 2025. Contributors to this edition include partners G.J. Ligelis Jr., Evan A. Hill, Andrew M. Wark, Bethany A. Pfalzgraf and Edward O. Minturn.

Publications

January 16, 2026

HLS Forum on Corporate Governance Publishes Cravath’s Q3 2025 Newsletter on M&A, Activism and Corporate Governance

On January 15, 2026, the Harvard Law School Forum on Corporate Governance published Cravath’s latest quarterly newsletter on M&A, activism and corporate governance. The newsletter provides insight into practical points, key takeaways and relevant developments across the M&A, activism, restructuring, regulatory and corporate governance landscape during the third quarter of 2025. Contributors to this edition include partners G.J. Ligelis Jr., Evan A. Hill, Michael L. Arnold, Andrew M. Wark, Bethany A. Pfalzgraf and Edward O. Minturn.

Publications

October 24, 2023

SEC Adopts Rule Amendments To Modernize Beneficial Ownership Reporting

On October 20, 2023, Cravath prepared a memo for its clients entitled “SEC Adopts Rule Amendments To Modernize Beneficial Ownership Reporting.” The memo examines the U.S. Securities and Exchange Commission’s recently adopted final rule amendments to modernize beneficial ownership reporting under Sections 13(d) and 13(g) of the Securities Exchange Act of 1934. The memo outlines the final rule amendments’ changes and guidance related to deadlines and cut‑off times for Schedule 13D and Schedule 13G filings, structured data language, the application of Regulation 13D-G to certain derivative securities and the definition of “group” in existing statutory language.

Publications

March 17, 2023

Andrew Wark and Maggie Segall Author Chapter on U.S. Antitrust Enforcement Trends in Deal‑Making for the International Comparative Legal Guide’s “Mergers & Acquisitions 2023”

Cravath partners Andrew M. Wark and Margaret T. Segall authored a chapter for the International Comparative Legal Guide’s “Mergers & Acquisitions 2023,” which provides cross border insights into mergers and acquisitions and was published by Global Legal Group on March 16, 2023. The chapter, entitled “Key Drivers and Trends: Deal‑Making in an Era of Heightened Antitrust Enforcement,” examines how companies considering M&A transactions in the United States have faced an evolving antitrust landscape, including changed enforcement practices and merger review procedures.

Publications

December 01, 2022

Jed Zobitz, Paul Zumbro and Andrew Wark Co‑Author U.S. Chapter of Lexology Getting The Deal Through’s “Distressed M&A 2023”

Cravath partners George E. Zobitz, Paul H. Zumbro and Andrew M. Wark co‑authored the United States chapter of Lexology Getting The Deal Through’s “Distressed M&A 2023,” which was published in November 2022. The chapter surveys the current market climate and legal framework for distressed M&A and provides a comprehensive overview of these transactions. The authors address relevant considerations involving transaction structures and sale process, due diligence, valuation and financing, documentation, regulatory and judicial approvals, and dispute resolution.

Cravath Bicentennial

Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.

Explore

Cravath, Swaine & Moore LLP Logo
  • CONTACT US
  • OUR STORY
  • ALUMNI PORTAL
  • DISCLAIMERS & NOTICES

Attorney Advertising. ©2026 Cravath, Swaine & Moore LLP.